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Abstract
Background
Subjects at risk for major mood disorders have a higher risk to develop autoimmune thyroid
disease (AITD) and vice-versa, implying a shared pathogenesis. In mood disorder patients,
an abnormal profile of hematopoietic/neuronal growth factors is observed, suggesting that
growth/differentiation abnormalities of these cell lineages may predispose to mood disor-
ders. The first objective of our study was to investigate whether an aberrant profile of these
hematopoietic/neuronal growth factors is also detectable in subjects at risk for AITD. A sec-
ond objective was to study the inter relationship of these factors with previously determined
and published growth factors/cytokines in the same subjects.
Methods
We studied 64 TPO-Ab-negative females with at least 1 first- or second-degree relative with
AITD, 32 of whom did and 32 who did not seroconvert to TPO-Ab positivity in 5-year follow-
up. Subjects were compared with 32 healthy controls (HCs). We measured serum levels of
brain-derived neurotrophic factor (BDNF), Stem Cell Factor (SCF), Insulin-like Growth Fac-
tor-Binding Protein 2 (IGFBP-2), Epidermal Growth Factor (EGF) and IL-7 at baseline.
Results
BDNF was significantly lower (8.2 vs 18.9 ng/ml, P<0.001), while EGF (506.9 vs 307.6 pg/
ml, P = 0.003) and IGFBP-2 (388.3 vs 188.5 ng/ml, P = 0.028) were significantly higher in
relatives than in HCs. Relatives who seroconverted in the next 5 years had significantly
higher levels of SCF than non-seroconverters (26.5 vs 16.7 pg/ml, P = 0.017). In a cluster
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analysis with the previously published growth factors/cytokines SCF clustered together with
IL-1β, IL-6 and CCL-3, of which high levels also preceded seroconversion.
Conclusion
Relatives of AITD patients show aberrant serum levels of 4 hematopoietic/neuronal growth
factors similar to the aberrancies found in mood disorder patients, suggesting that shared
growth and differentiation defects in both the hematopoietic and neuronal systemmay
underlie thyroid autoimmunity and mood disorders. A distinct pattern of four inter correlating
immune factors in the relatives preceded TPO-Ab seroconversion in the next 5 years.
Introduction
Autoimmune hypothyroidism is characterized by a combination of clinical features, elevated
serum TSH with reduced free T4 (FT4) levels, the presence of serum antibodies against thyroid
antigens, and reduced echogenicity of the thyroid sonogram [1]. It is the most common organ-
specific autoimmune disorder with an estimated prevalence of 2%, with a higher prevalence in
women and depending on iodine intake [2–5]. Thyroid peroxidase (TPO) is the major autoan-
tigen and TPO antibodies (TPO-Abs) are present in almost all patients with autoimmune
hypothyroidism [6] and precede the clinical phase of autoimmune hypothyroidism by many
years. Subclinical autoimmune hypothyroidism (the presence of TPO-Abs with raised TSH
and normal FT4 levels) is even more prevalent and affects about 9% of the population [2, 5]. In
the Whickham follow-up study, women with TPO-Abs had an eight-fold higher risk of devel-
oping clinically overt hypothyroidism over 20 years than did antibody-negative women [7]. In
our own studies on the Amsterdam AITD cohort (euthyroid females with at least one first or
second degree relative with a documented autoimmune hyper- or hypothyroidism) TPO-Ab
positivity at the start of the study also represented a higher risk to develop overt hypothyroid-
ism in a follow-up of 5 years [8, 9]. In addition, there was a higher conversion rate from
TPO-Abs negativity to positivity, showing a familial proneness for thyroid autoimmune reac-
tivity [9, 10].
In another previous study on this cohort, we tested the hypothesis that serum levels of fac-
tors related to thyroid growth and connective tissue abnormalities (Platelet-Derived Growth
Factor (PDGF)-BB, Fibronectin, Metalloproteinase (MMP)-13), to the early accumulation of
immune cells in the thyroid (soluble Vascular Cell Adhesion Molecule (sVCAM)-1, CCL2,
CCL4, Angiopoetin-1 Receptor-2 (TIE-2)), and to inflammation (IL-1β, IL-6 and CCL3) were
related to this proneness for thyroid autoimmunity in the relatives [11]. We therefore studied
these factors in the serum of 64 TPO-Ab negative euthyroid relatives, 32 of whom did and 32
of whom did not seroconvert to TPO-Abs positivity in 5 year follow-up. The relatives were
compared with 32 healthy controls. We found that both seroconverting and non-seroconvert-
ing relatives showed an up regulation of Fibronectin and a down regulation of PDGF-BB,
CCL2, CCL4, sVCAM-1, TIE-2 and MMP-13. The relatives who later seroconverted (serocon-
verters, SCs) differed from those who did not seroconvert (non-seroconverters, NSCs) by a sig-
nificant up regulation of pro-inflammatory compounds, such as IL-1β, IL-6 and CCL3. We
concluded that euthyroid females within AITD families show a characteristic pattern of abnor-
malities in serum levels of growth factors, chemokines, adhesion molecules and cytokines, sug-
gesting an already compromised thyroid-immune system interaction in the euthyroid family
members. Also, pre-seroconversion stages might be predicted using serum analytes pointing to
a higher inflammatory state.
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Autoimmune hypothyroidism is commonly accompanied by depressive symptoms. A large
epidemiological Danish nationwide, prospective cohort study showed that various autoim-
mune diseases including AITD, are associated with subsequent lifetime mood disorder diagno-
sis (e.g. bipolar affective disorder, unipolar depression, psychotic depression and other
remaining mood disorders) [12]. In hypothyroid patients the lack of thyroid hormone in the
brain is likely an important determinant for these mood disturbances [13]. However, a deficit
of thyroid hormone may not be the only cause, as even subjects with TPO-Abs with normal
thyroid function have a higher risk to develop anxiety disorders and mood disorders [14]. Also
offspring of patients with a bipolar affective disorder have a higher prevalence of TPO-Abs,
even if they are not affected by the psychiatric disorder [15, 16]. In addition, a higher preva-
lence of TPO Abs and autoimmune hypothyroidism has been reported in patients with bipolar
affective disorder, irrespective of the usage of lithium [17, 18]. Taken together, these associa-
tions might imply a shared immune pathogenesis for both AITD and mood disorders.
We therefore additionally determined, in the sera used in the previous study, 5 growth and
differentiation factors that have repeatedly been shown to be abnormally expressed in the circu-
lation of mood disorder patients and that are capable of influencing both immune and/or neu-
ronal cell growth, i.e. SCF, IGFBP-2, EGF, BDNF and IL-7 [19–23]. In addition we studied the
inter relationship of these factors with the previously determined factors using a cluster analy-
sis to study patterns of TPO-Ab seroconversion [11].
Subjects and Methods
Subjects
The Amsterdam AITD cohort has previously been described in detail [8]. In the present study,
we studied serum levels of several hematopoietic/neuronal growth factors in the subjects. In
addition we assessed the association with TPO-Ab seroconversion like we previously did in the
study of Beumer et al [11]. Therefore, 32 euthyroid subjects were selected who were TPO-Ab
and Tg-Ab negative at baseline but developed TPO-Abs during follow-up without developing
an abnormal TSH. Each selected SC was matched with an euthyroid subject who was TPO-Ab
and Tg-Ab negative at baseline and did not develop TPO-Abs (non-seroconverter) up to the
time at which the SC to whom they were matched had received her endpoint. SCs and NSCs
were matched for age, current smoking, current estrogen use, and duration of follow-up.
As a control group, we selected 32 female subjects from an ongoing program for delineating
reference values of endocrine function tests that were in self-proclaimed good health, were not
using chronic medication (except for oral contraceptives), had no family or personal history of
thyroid disease, and had normal TSH and no thyroid antibodies. Blood samples were collected
over the same period of time as those of the Amsterdam AITD cohort and were processed in
the same manner.
All subjects gave informed written consent and the Medical Ethics Committee of the Aca-
demic Medical Center in Amsterdam and the Medical Ethics Committee of Erasmus Medical
Center in Rotterdam approved the study.
TSH, FT4 and TPO-Ab determinations
Serum samples were stored at −20°C until determination of the study parameters. Serum TSH
and FT4 were measured using time-resolved fluoroimmunoassay (Delphia, Turku, Finland). Ref-
erence values are 0.4–5.7 mU/L for TSH and 9.3–20.1 pmol/L for FT4. TPO-Abs and Tg-Abs
were measured by chemiluminescence immunoassays (LUMI test anti-TPO and LUMI test anti-
thyroglobulin, respectively; Brahms, Berlin, Germany). Improved versions of both assays became
available during follow-up: the detection limits of these new assays were 30 kU/L for TPO-Abs
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and 20 kU/L for Tg-Abs. The TPO-Ab concentrations obtained with the old assay were multi-
plied by a factor 0.72 to obtain comparative values in the new assay. TPO-Ab and Tg-Ab concen-
trations were considered to be positive at values greater than 100 kU/L.
Serum growth factors
We studied a panel of five growth factors at baseline: SCF, IGFBP-2, EGF, BDNF and IL-7.
Serum concentrations were measured using the bead-based Luminex system. These multi-
plexed sandwich immunoassays were developed from commercially available capture and
detection antibodies (R&D systems) and standard proteins, validated and approved at Myriad-
EDI-GmbH (Reutlingen, Germany) according to methods described previously [24]. Subject
and healthy control samples were run singular. Assays were measured on either the Luminex
FlexMap-3D or Luminex 200 system. Results are expressed as picograms per ml or nanograms
per ml.
EGF, IL-7, SCF, BDNF were measureable in all samples. For IGFBP-2 6.6% of the values
were above the detection limit. Values above the detection limit were set to the highest value
observed (IGFBP-2: 19666.5 ng/ml).
Statistics
Test assumptions were checked by plotting of the data and depending on the distribution pat-
tern, parametric (Student’s T-test) or nonparametric group comparisons (Mann-Whitney U
test) were used for unadjusted group comparisons. All analyses comparing HC, SC and NSC
groups were subsequently adjusted, for which we used ANOVA. We adjusted for smoking, the
usage of oral contraceptives, age, BMI and FT4 levels. Because SCs and NSCs were matched for
age, smoking and estrogen use we did not adjust for these factors when comparing SCs and
NSCs. If necessary we transformed dependent variables by the natural logarithm. In order to
improve the interpretability of the group estimates, data are expressed as median with 95%
confidence intervals which were calculated using a bootstrap procedure with 1000 draws. For
IGFBP-2, residuals of the regression analyses remained non-normal after transformation due
to outliers (n = 8), however, we can reliably report the outcomes of the regression analyses as
these were in line with unadjusted non-parametric results and also remained similar after
exclusions of the outliers.
In addition a dendrogram was constructed by SPSS using hierarchical cluster analysis of the
serum analytes using the between-groups linkage method. For this analysis, we selected ana-
lytes from the previous study that were significantly different between healthy controls and
subjects or between NSCs and SCs (S1 Table) and were part of a cluster in that study, and com-
bined them with the levels of growth and differentiation factors assessed in the current study
[11]. The associations between TSH, FT4 and the serum growth factors were analyzed by linear
regression analyses. Level of significance was set at P<0.05 (2 tailed). Statistical analysis was
performed using SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, NY, USA).
Results
As a result of the matching procedure, SCs and NSCs were not different regarding age, current
smoking behavior, Body Mass Index (BMI), current estrogen use and TSH or FT4 levels
(Table 1). None of the subjects were using chronic medication. TSH levels were not associated
with any of the growth and differentiation factors (data not shown). FT4 levels were positively
associated with IGFBP-2 levels (β±SE 0.16 ±0.075; P = 0.037) and we observed a non-signifi-
cant trend with SCF (β±SE 1.2 ±0.68; P = 0.069). FT4 was not associated with the other growth
factors.
Growth and Differentiation Factors in Women at Risk for AITD
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Subjects versus healthy controls
Table 2 shows the median levels of the 5 tested growth and differentiation factors in the healthy
controls and in the subjects. IGFBP-2 levels were significantly higher in the relatives than in
the healthy controls (P = 0.028). Serum levels of EGF were also significantly higher in the rela-
tives than in the healthy controls (P = 0.003). Serum levels of BDNF were significantly lower in
the relatives than in the healthy controls (P<0.001). Serum levels of SCF and IL-7 were not sta-
tistically different between relatives and healthy controls.
Seroconverters versus non-seroconverters
Table 3 shows that SC subjects had significantly higher levels of SCF than NSC subjects
(P = 0.017). Serum levels of SCF were not statistically different between SCs and healthy controls
and between NSCs and healthy controls (P = 0.49 and P = 0.26, respectively). The serum levels of
IGFBP-2, EGF, BDNF and IL-7 were not significantly different between SCs and NSCs. Serum
levels of EGF were significantly higher in SCs and in NSCs than in healthy controls (P = 0.017
and P = 0.011, respectively). Serum levels of BDNF were significantly lower in SCs and in NSCs
than in healthy controls (P<0.001 in both groups). A non-significant trend towards lower levels
of IL-7 in the SCs than in controls was observed (P = 0.076). IGFBP-2 levels were higher in both
groups of subjects than in healthy controls which was significant in the NSCs (P = 0.019).
Cluster analysis
Taking the analytes which we have previously determined also into account we found in the
cluster analysis two mutually correlating clusters of analytes: one stronger inter correlating
Table 1. Baseline characteristics.
P-values
Controls SC NSC SC vs C NSC vs C NSC vs SC
Number of subjects 30 30 31
Age, mean (range) 35.2 (21–61) 33.3 (18–61) 33.5 (19–62) 0.5 0.56 0.93
BMI, mean (range) 22.7 (18–33) 24.1 (19–41) 24.2 (19–42) 0.22 0.17 0.95
Current smoking, % 12 (40%) 14 (46%) 14 (45%) 0.61 0.69 0.9
Current estrogen use, % 5 (17%) 11 (37%) 12 (38%) 0.055 0.083 0.87
TSH, median (95% CI) 1.3 (1.1–1.7) 1.4 (1.3–1.7) 1.2 (1–1.5) 0.36 0.66 0.13
FT4, median (95% CI) 13.2 (12.9–14.6) 12.8 (12.4–13.5) 13.7 (13–14.2) 0.53 0.60 0.25
Characteristics of healthy controls (C) and relatives of AITD patients grouped for TPO antibody conversion during follow-up (seroconverters (SC) and non
seroconverters (NSC)). Due to a lack of serum, the total number of subjects per group is not equal to the original 32.
doi:10.1371/journal.pone.0153892.t001
Table 2. Comparison of growth and differentiation factors between healthy controls and subjects.
Controls Subjects P-value Adjusted P-value
EGF (pg/ml) 307.6 (110–409) 506.9 (428–612) 0.001 0.003
BDNF (ng/ml) 18.9 (14.6–22.7) 8.2 (7.3–9.3) <0.001 <0.001
IGFBP-2 (ng/ml) 177.8 (142–235) 252.5 (177–351) 0.073 0.028
SCF (pg/ml) 22.6 (17.4–26.4) 22.6 (16.7–27.1) 0.58 0.70
IL-7 (pg/ml) 4.0 (2.8–5.1) 3.7 (3.0–3.8) 0.18 0.26
Median levels (95% CI) of EGF, BDNF, IGFBP-2, SCF and IL-7 in healthy controls and in subjects overall. Adjusted P-values are adjusted for age, BMI,
smoking, oral contraceptive usage and FT4 levels.
doi:10.1371/journal.pone.0153892.t002
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cluster A and a weaker inter correlating cluster B (Fig 1) [11]. Cluster A contained the inflam-
matory cytokines/chemokines IL-1β, CCL3 and IL-6, the connective tissue modulator MMP-
13 and the hematopoietic/neuronal growth and differentiation factor SCF, while cluster B con-
tained the pro-inflammatory chemokines CCL2 and CCL4, the endothelial adhesion molecule
Table 3. Serum levels of growth and differentiation factors in healthy controls (C), Seroconverting (SC) and Non-Seroconverting (NSC) family
members.
Adjusted P-value
Controls SC NSC SC vs C NSC vs C SC vs NSC
EGF (pg/ml) 307.6 (110–409) 564.2 (411–803) 470.6 (355–612) 0.017 0.011 0.79
BDNF (ng/ml) 18.9 (14.6–22.7) 8.7 (5.1–10.8) 8.1(6.9–9.3) <0.001 <0.001 0.45
IGFBP-2(ng/ml) 177.8 (142–235) 233.2 (153–376) 252.5 (164–390) 0.16 0.019 0.31
SCF (pg/ml) 22.6 (17.4–26.4) 26.5 (22.5–31.9) 16.7 (12.3–22.8) 0.49 0.26 0.017
IL-7 (pg/ml) 4.0 (2.8–5.1) 3.4 (2.7–3.8) 3.7 (3.0–4.0) 0.076 0.55 0.25
Median levels (95% CI) of EGF, BDNF, IGFBP-2, SCF and IL-7.
doi:10.1371/journal.pone.0153892.t003
Fig 1. Cluster analysis. Heat map of hierarchical cluster analysis of the serum levels of cytokines, chemokines, growth factors and tissue remodeling factors
in the relatives. Color-coded correlation matrix illustrates Pearson’s correlation coefficients. Significant positive correlations are given in the red scale
(darkest red are correlation coefficients > 0.50), and significant negative correlations are given in the (dark) green scale. Lighter fields are not significant. In
addition, a dendrogram is presented as a result of the hierarchical clustering. A indicates cluster A and B indicates cluster B.
doi:10.1371/journal.pone.0153892.g001
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sVCAM-1, PDGF-BB, and the T cell and NK cell growth factor IL-7. The heat map shows that
the growth factors IGFBP-2, EGF and BDNF barely correlated to each other and to the other
analytes.
Regarding the pattern of expression in the two study groups (SCs and NSCs) three patterns
of reactivity could be detected (S1 Table and Table 4). There were factors, which were higher in
the serum of both SCs and NSCs than in controls, such as the growth factors IGFBP-2, EGF
and the repair factor Fibronectin. There were also factors that were lower in the serum of both
SCs and NSCs than in controls, such as CCL4, CCL2, sVCAM-1, BDNF and PDGF-BB. Finally,
there were factors that were higher in the SCs than in the NSCs such as IL1-β, IL-6, CCL3 and
SCF (S1 Table and Table 4).
Discussion
The present study shows that euthyroid females, who are relatives of AITD patients and at risk
of developing AITD, have an aberrant serum level of 4 of the 5 tested hematopoietic/neuronal
growth and differentiation factors, i.e. of BDNF, IGFBP-2, EGF and SCF. BDNF levels were sig-
nificantly lower and IGFBP-2 and EGF higher expressed in sera of the relatives of the AITD
patients (in both SCs and NSCs) than in healthy controls. IL-7 levels were normal. We also
found in the healthy relatives, who converted in the following 5 years to TPO-Ab positivity, sig-
nificantly higher serum levels of SCF than in relatives who did not.
It is of note that the 5 studied factors have been highlighted as serum biomarkers for major
mood disorders in several studies [19–23] and are involved in neurogenesis, neuroprotection
and hematopoietic differentiation [25–29]. This is in particular known for BDNF.
Table 4. Patterns of expression levels of cytokines, chemokines and growth and differentiation fac-
tors, assessed in the previous study of Beumer et al. and in the current study [7].
NSC vs HC SC vs NSC SC vs HC
Pattern 1
Fibronectin (μg/ml) ""  ""
IGFBP-2 (ng/ml) ""  
EGF (pg/ml) ""  ""
Pattern 2
CCL4 (pg/ml) ##  ##
MMP-13 (ng/ml) ##  ##
CCL2 (pg/ml) ##  
sVCAM-1 (μg/ml) ##  ##
PDGF-BB (pg/ml) ##  ##
BDNF (ng/ml) ##  ##
Pattern 3
IL-1β (pg/ml) ## "" 
IL-6 (pg/ml) ## "" 
CCL3 (pg/ml) ## "" 
SCF (pg/ml)  "" 
Other
IL-7 (pg/ml)   
Patterns of expression levels in serum compounds between seroconverters (SC) and non-seroconverters
(NSC) and healthy controls (HC). "" and ## indicates signiﬁcantly higher or lower serum levels respectively,
and  indicates that serum levels are not signiﬁcantly different (S1 Table).
doi:10.1371/journal.pone.0153892.t004
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Neurotrophic factors, like BDNF, play an important role in neuronal plasticity, modulating not
only axonal and dendritic growth and remodeling, but also neurotransmitter release and syn-
apse formation [30, 31]. Neuronal plasticity is a complex process which is illustrated by the
complex interaction between the neurotrophic factors and its receptors. The cellular actions of
BDNF, for example, are mediated through TrkB (tyrosine kinase receptor) and by p75 neuro-
trophin receptor (p75NTR) [32]. Binding of dimeric BDNF causes dimerization of TrkB recep-
tor and autophosphorylation of intracellular tyrosine residues. Activation of TrkB receptor
leads to signaling cascades involving activation of Ras/ERK pathway, phosphatidylinositol
3-kinase (PI3K) and Phospholipase Cγ [33]. The Ras pathway regulates neuronal survival and
differentiation through downstream signaling that includes c-RAF/B-Raf/ERK1/ERK2. Bru-
noni et al. showed in a meta-analysis that BDNF levels were decreased in patients with a major
depressive disorder and were also associated with clinical changes in depression [34].
This study also extends our previous study and shows that the here reported 5 growth fac-
tors and the previously reported 9 growth factor/cytokines form three patterns of reactivity in
the relatives of AITD patients when compared to healthy subjects and depending on TPO-Ab
seroconversion within the next 5 years [11]. This study and the previous one therefore under-
score the widespread changes in immune-neuro-endocrine molecular networks that apparently
precede the appearance of TPO-Abs, which opens avenues for developing assays for the detec-
tion of individuals at risk for thyroid autoimmunity.
Combining this study with the previous one we found factors which were raised in the rela-
tives, irrespective of later seroconversion, such as the growth factors IGFBP-2, EGF and the
repair factor Fibronectin. None of these factors inter correlated. There were also factors that
were reduced in the serum of the relatives irrespective of later seroconversion, such as the che-
mokines CCL4, CCL2, the adhesion molecule sVCAM-1, and the growth factors BDNF and
PDGF-BB. Many of these factors inter correlated in cluster B in the dendrogram constructed in
this article. Taken these two patterns of reactivity together, the serum aberrancies suggest
another state of growth regulation of multiple cell lines (including neuronal and hematopoietic
cells) and another state of leukocyte migration in relatives of AITD patients.
Finally, there were factors that were higher in the SCs than in the NSCs such as IL1-β, IL-6,
CCL3 and SCF, while often being lower in the NSCs than in controls. These factors correlated
to each other in cluster A in the dendrogram. We assume that the generally low expression in
NSCs in cluster A reflects an immune suppressive state preventing autoimmunity, while a rise
of these pro-inflammatory compounds precedes a conversion to TPO-Ab positivity and thus
may reflect a very early stage of thyroid auto reactivity. In recent studies, the importance of T
helper 1 lymphocytes in the induction of such auto-inflammatory state has been shown [35]. A
further investigation of cytokines and chemokines reflecting the higher state of the T helper 1
system (such as IL-12, IFN-γ and CXCL-10) in relatives of AITD index cases deserves further
attention [36, 37].
A limitation of our study is the relatively small sample size. Also, because this is an explor-
ative study which focused on 5 non-random selected analytes, we did neither take type I errors
into account nor applied a correction for multiple testing. Our study is also limited by the fact
that we did not assess the association between the levels of these growth and differentiation fac-
tors and the mood state of the relatives (sampling of the sera occurred 15 years ago, at the time
we were unaware of the link between AITD and depression). Next, we used a BDNF antibody
in our immunoassay, which was developed to measure mature BDNF. It is now known that
there are other assays and antibodies on the market that also measure pro-BDNF [38]. It has
been reported, however, that in particular mature BDNF is important in major depression [39]
although this needs exploration. Furthermore, also other factors important in neuronal growth
and differentiation should be taken into account, such as glial-cell-line-derived neurotrophic
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factor (GDNF). GDNF signals through a multicomponent receptor complex comprising the
Ret proto-oncogene (RET) tyrosine kinase and the GDNF family receptor (GFR)α [40]. Fol-
lowing GDNF binding in the presence of co-receptor GFRα, RET becomes dimerized and tyro-
sine phosphorylated and triggers different pathways (Ras-MAPK, PI3K-Akt). Finally, in the
paragraph above, we have highlighted that other immune factors which are linked to the induc-
tion of thyroid autoimmunity (such as T helper 1 related factors) should be explored. It is also
evident that our studies need confirmation and expansion in larger families and follow-up
studies, taking many more neuronal, endocrine and immune factors into consideration to
unravel the changes in immune-neuro-endocrine molecular networks that precede and proba-
bly underlie the development of AITD and mood disorders.
Since a large number of autoimmune hypothyroid patients have a diminished cognitive and
psychological function despite adequate levothyroxine replacement therapy, another next step
could be to measure the growth and differentiation factors in these patients and to assess the
association with these symptoms.
We conclude that subjects at risk for AITD show changes in growth and differentiation fac-
tors in serum, which are both active as neuronal and hematopoietic growth and differentiation
factors and are abnormally expressed in patients with mood disorders. This suggests that
shared growth and differentiation defects in both the hematopoietic and neuronal system may
underlie both thyroid autoimmunity and mood disorders.
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